Alpha Cognition Inc. Common Stock (ACOG)
$
9.33
-0.76 (-8.15%)
Key metrics
Financial statements
Free cash flow per share
-0.4602
Market cap
144.9 Million
Price to sales ratio
49.4791
Debt to equity
0
Current ratio
17.1401
Income quality
0.6308
Average inventory
749.3 Thousand
ROE
-0.4943
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
News
seekingalpha.com
Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.
zacks.com
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (the “Company” or “Alpha Cognition”) today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the “AAIC”), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially laun.
seekingalpha.com
Alpha Cognition Inc. (NASDAQ:ACOG ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Henry Du - Interim Chief Financial Officer Michael McFadden - Chief Executive Officer Lauren D'Angelo - Chief Operating Officer Conference Call Participants Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings, and welcome to the Alpha Cognition Earnings Call. At this time, all participants are in a listen-only mode.
businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team,” said Michael McFadden, Chief Executive Officer. “In early 2025, we completed the manufacturing of the initial commercial supply of ZUNVEYL.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the.
See all news
